NEW YORK – Nottingham, UK-based Oncimmune said on Wednesday that it is evaluating the ability of its antibody profiling technology, SeroTag, to identify best responders to immune checkpoint inhibitors under development at an unnamed biopharmaceutical firm.
Under the collaboration with the drug firm, Oncimmune will use SeroTag to evaluate the antibody profiles of patients enrolled in a checkpoint inhibitor clinical trial and identify tumor-associated biomarkers and characteristics that could predict response to therapy or the onset of immune-related adverse events. Oncimmune expects to complete the profiling program in the second quarter of 2021.
SeroTag, a multiplex, high-throughput technology, utilizes a large in-house protein library and a repository of data on autoimmune diseases, cancer, and other illnesses. Oncimmune hopes to first validate its technology through a series of pilot studies before entering into a larger partnership to profile patients in a range of immune-oncology clinical trials.
SeroTag is one of the tools offered through Oncimmune's ImmunoINSIGHTS services, which offers a range of tests for stratifying participants into clinically relevant subgroups in drug development studies. This is the fourth partnership with a drug developer inked by Oncimmune in less than four months.